100 related articles for article (PubMed ID: 15120940)
1. Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells.
Kawano T; Horiguchi-Yamada J; Saito S; Iwase S; Furukawa Y; Kano Y; Yamada H
Leuk Res; 2004 Jun; 28(6):623-9. PubMed ID: 15120940
[TBL] [Abstract][Full Text] [Related]
2. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells.
Kohmura K; Miyakawa Y; Kawai Y; Ikeda Y; Kizaki M
J Cell Physiol; 2004 Mar; 198(3):370-6. PubMed ID: 14755542
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
Kawano T; Horiguchi-Yamada J; Iwase S; Furukawa Y; Kano Y; Yamada H
Mol Cell Biochem; 2004 Mar; 258(1-2):25-33. PubMed ID: 15030167
[TBL] [Abstract][Full Text] [Related]
5. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
6. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
Kawano T; Horiguchi-Yamada J; Iwase S; Akiyama M; Furukawa Y; Kan Y; Yamada H
Anticancer Res; 2004; 24(5A):2705-12. PubMed ID: 15517875
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
[TBL] [Abstract][Full Text] [Related]
8. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis.
Jakubowska J; Wasowska-Lukawska M; Czyz M
Eur J Pharmacol; 2008 Oct; 596(1-3):41-9. PubMed ID: 18782571
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
10. Role of ERK activation in growth and erythroid differentiation of K562 cells.
Woessmann W; Mivechi NF
Exp Cell Res; 2001 Apr; 264(2):193-200. PubMed ID: 11262176
[TBL] [Abstract][Full Text] [Related]
11. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.
Honma Y; Okabe-Kado J; Hozumi M; Uehara Y; Mizuno S
Cancer Res; 1989 Jan; 49(2):331-4. PubMed ID: 2910452
[TBL] [Abstract][Full Text] [Related]
12. ERK1/2 inactivation and p38 MAPK-dependent caspase activation during guanosine 5'-triphosphate-mediated terminal erythroid differentiation of K562 cells.
Moosavi MA; Yazdanparast R; Lotfi A
Int J Biochem Cell Biol; 2007; 39(9):1685-97. PubMed ID: 17543571
[TBL] [Abstract][Full Text] [Related]
13. ERK/MAPK pathway is required for changes of cyclin D1 and B1 during phorbol 12-myristate 13-acetate-induced differentiation of K562 cells.
Lee CH; Yun HJ; Kang HS; Kim HD
IUBMB Life; 1999 Dec; 48(6):585-91. PubMed ID: 10683762
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
16. Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.
Brózik A; Casey NP; Hegedus C; Bors A; Kozma A; Andrikovics H; Geiszt M; Német K; Magócsi M
Ann N Y Acad Sci; 2006 Dec; 1090():344-54. PubMed ID: 17384279
[TBL] [Abstract][Full Text] [Related]
17. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
18. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
Sawafuji K; Miyakawa Y; Weisberg E; Griffin JD; Ikeda Y; Kizaki M
Leuk Lymphoma; 2003 Nov; 44(11):1987-96. PubMed ID: 14738154
[TBL] [Abstract][Full Text] [Related]
19. Activin A induces erythroid gene expressions and inhibits mitogenic cytokine-mediated K562 colony formation by activating p38 MAPK.
Huang HM; Chiou HY; Chang JL
J Cell Biochem; 2006 Jul; 98(4):789-97. PubMed ID: 16440334
[TBL] [Abstract][Full Text] [Related]
20. ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent.
Woessmann W; Zwanzger D; Borkhardt A
Cell Biol Int; 2004; 28(5):403-10. PubMed ID: 15193284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
